# Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

> **NCT04270175** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 15 (actual)

## Conditions studied

- Amyloid
- AL Amyloidosis
- Refractory AL Amyloidosis

## Interventions

- **DRUG:** Daratumumab SC
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04270175
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-14
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04270175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04270175, "Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04270175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*